Immune microenvironment and immunotherapy of pituitary adenomas

doi:10.16352/j.issn.1001-6325.2022.01.034

Abstract

Abstract: Pituitary adenomas (PAs) are the second most common primary central nervous system tumors. Although most PAs can be cured by surgical operation, medicine treatment or radiotherapy, some PAs may recur, invade adjacent structures or even metastasize to other organs after traditional treatments, so decreaseing patient overall survival and deteriorate their life quality. In recent years, studies on the immune microenvironment of brain tumors emerged, especially in the field of glioma, providing potential effective treatment targets for immunotherapy and setting the foundation for improving patient survival. However, previous studies have only conducted preliminary analyses on immune cells, immune molecules, and cytokines in the microenvironment of PAs. The research on immunotherapy of PAs with animal model and humans is only at an early phase.

Key words: pituitary adenoma, immune microenvironment, immunotherapy

CLC Number:

R739.41

GUO Xiao-peng, XING Bing, MA Wen-bin. Immune microenvironment and immunotherapy of pituitary adenomas[J]. Basic & Clinical Medicine, 2022, 42(1): 173-178.

References

[1]Ostrom QT, Patil N, Cioffi G, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017[J]. Neuro Oncol, 2020, 22: iv1-iv96.
[2]Dai C, Liang S, Sun B, et al. The progress of immunotherapy in refractory pituitary adenomas and pituitary carcinomas[J]. Front Endocrinol (Lausanne), 2020, 11: 608422. doi: 10.3389/fendo.2020.608422.
[3]Wang Z, Guo X, Gao L, et al. The immune profile of pituitary adenomas and a novel immune classification for predicting immunotherapy responsiveness[J]. J Clin Endocrinol Metab, 2020, 105: e3207-e3223. doi: 10.1210/clinem/dgaa449.
[4]Marques P, Grossman AB,Korbonits M. The tumour microenvironment of pituitary neuroendocrine tumours[J]. Front Neuroendocrinol, 2020, 58: 100852. doi: 10.1016/j.yfrne.2020.100852.
[5]Ilie MD, Vasiljevic A, Raverot G, et al. The microenvironment of pituitary tumors-biological and therapeutic implications[J]. Cancers (Basel), 2019, 11: 1605. doi: 10.3390/cancers11101605.
[6]Mei Y, Bi WL, Agolia J, et al. Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression[J]. Pituitary, 2021, 24: 359-373.
[7]Wang PF, Wang TJ, Yang YK, et al. The expression profile of PD-L1 and CD8(+) lymphocyte in pituitary adenomas indicating for immunotherapy[J]. J Neurooncol, 2018, 139: 89-95.
[8]Marques P, Barry S, Carlsen E, et al. Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours[J]. Acta Neuropathol Commun, 2019, 7: 172. doi: 10.1186/s40478-019-0830-3.
[9]Mei Y, Bi WL, Greenwald NF, et al. Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors[J]. Oncotarget, 2016, 7: 76565-76576.
[10]Iacovazzo D, Chiloiro S, Carlsen E, et al. Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours[J]. Endocrine, 2020, 67: 651-658.
[11]Barry S, Carlsen E, Marques P, et al. Tumor microenvironment defines the invasive phenotype of AIP-mutation-positive pituitary tumors[J]. Oncogene, 2019, 38: 5381-5395.
[12]Lu JQ, Adam B, Jack AS, et al. Immune cell infiltrates in pituitary adenomas: more macrophages in larger adenomas and more T cells in growth hormone adenomas[J]. Endocr Pathol, 2015, 26: 263-272.
[13]Sato M, Tamura R, Tamura H, et al. Analysis of tumor angiogenesis and immune microenvironment in non-functional pituitary endocrine tumors[J]. J Clin Med, 2019, 8: 695. doi: 10.3390/jcm8050695.
[14]Yagnik G, Rutowski MJ, Shah SS, et al. Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes[J]. Oncotarget, 2019, 10: 2212-2223.
[15]Giese MA, Hind LE,Huttenlocher A. Neutrophil plasticity in the tumor microenvironment[J]. Blood, 2019, 133: 2159-2167.
[16]Kemeny HR, Elsamadicy AA, Farber SH, et al. Targeting PD-L1 initiates effective antitumor immunity in a murine model of Cushing Disease[J]. Clin Cancer Res, 2020, 26: 1141-1151.
[17]Nomura R, Yoshida D,Teramoto A. Stromal cell-derived factor-1 expression in pituitary adenoma tissues and upregulation in hypoxia[J]. J Neurooncol, 2009, 94: 173-181.
[18]Arzt E, Buric R, Stelzer G, et al. Interleukin involvement in anterior pituitary cell growth regulation: effects of IL-2 and IL-6[J]. Endocrinology, 1993, 132: 459-467.
[19]Wu JL, Qiao JY,Duan QH. Significance of TNF-alpha and IL-6 expression in invasive pituitary adenomas[J]. Genet Mol Res, 2016, 15: 7502. doi: 10.4238/gmr.15017502.
[20]Lamb LS, Sim HW, McCormack AI. Exploring the role of novel medical therapies for aggressive pituitary tumors: a review of the literature-“are we there yet?”[J]. Cancers (Basel), 2020, 12: 308. doi: 10.3390/cancers12020308.
[21]Lin AL, Jonsson P, Tabar V, et al. Marked response of a hypermutated acth-secreting pituitary carcinoma to Ipilimumab and Nivolumab[J]. J Clin Endocrinol Metab, 2018, 103: 3925-3930.
[22]Caccese M, Barbot M, Ceccato F, et al. Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab[J]. Anticancer Drugs, 2020, 31: 199-204.
[23]Sol B, de Filette JMK, Awada G, et al. Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?[J]. Eur J Endocrinol, 2021, 184: K1-K5. doi: 10.1530/EJE-20-0151.
[24]Principe M, Chanal M, Ilie MD, et al. Immune lands-cape of pituitary tumors reveals association between macrophages and gonadotroph tumor invasion[J]. J Clin Endocrinol Metab, 2020, 105: 3459-3473.
[25]Tang X, Zhao S, Zhang Y, et al. B7-H3 as a novel CAR-T therapeutic target for glioblastoma[J]. Mol Ther Oncolytics, 2019, 14: 279-287.